ArticleAmerican journal of translational research2025
CXCL14 regulates ovarian endometriosis progression by targeting PCNA.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the regulatory function and mechanism of CXCL14 in endometriosis.
methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was used to examine the expression of CXCL14 in eutopic and ectopic endometrial stromal cells (ESCs) derived from patients with endometriosis and in situ endometrial stromal cells derived from healthy individuals. Alterations in cell proliferation and migration capabilities were assessed through Cell Counting Kit-8 (CCK8) and transwell assays following the silencing or overexpression of CXCL14. Mass spectrometry was employed to identify potential interacting proteins of CXCL14, and proliferating cell nuclear antigen (PCNA) was selected for further investigation. The regulatory mechanism of PCNA by CXCL14 was further examined using co-immunoprecipitation (co-IP), Western blotting, and cellular experiments.
resultsCXCL14 was highly expressed in ovarian endometriosis. The proliferative and migratory abilities of ESCs were positively correlated with CXCL14 expression levels. Moreover, CXCL14 interacted with PCNA. Silencing CXCL14 expression increased PCNA ubiquitination and promoted its degradation. Conversely, overexpression of PCNA mitigated the inhibitory effects of CXCL14 silencing on ESCs.
conclusionsCXCL14 may regulate PCNA through the ubiquitination pathway, thereby promoting the development and progression of endometrial stromal cells. This study provides new insights into the pathogenesis of endometriosis, highlighting the potential of CXCL14 as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.